Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study

Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study

ObjectiveSince 2016, the Chinese government has been regularly implementing the National Reimbursement Drug List Negotiation (NRDLN) to improve the accessibility of drugs. In the second round of NRDLN in July 2017, 18 anticancer drugs were included. This study analyzed the impact of the NRDLN on the...

Full description

Bibliographic Details
Main Authors: Hong Zhu, Jingmin Zhu, Yingyu Zhou, Linghan Shan, Cui Li, Yu Cui, Zheng Kang, Mingli Jiao, Huan Liu, Lijun Gao, Qunhong Wu, Yanhua Hao
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Public Health
Subjects:
accessibility
availability
cost
anticancer drugs
National Reimbursement Drug List Negotiation
China
Online Access:https://www.frontiersin.org/articles/10.3389/fpubh.2022.921093/full

Internet

https://www.frontiersin.org/articles/10.3389/fpubh.2022.921093/full

Similar Items